question: Compared to placebo what was the result of  etoricoxib 90 mg once daily,  naproxen 500 mg twice daily on Patient global assessment of disease activity; investigator global assessment of disease activity; Tender joint count; Swollen joint count; Patient global assessment of pain;Health Assessment Questionnaire disability ; Serum C-reactive protein; ACR20 responder criteria; Discontinuation due to lack of efficacy ?
context:  The most common reason for discontinuation was lack of efficacy, and significantly more patients discontinued due to lack of efficacy in the placebo group than in the etoricoxib and naproxen group (25.2%, 12.5%, 10.5%, respectively, p<0.001 vs placebo)